Will My Child Inherit Gaucher Disease?
At a Glance
Gaucher disease is an autosomal recessive condition, meaning a child must inherit a mutated GBA1 gene from both parents to get the disease. If you have Gaucher disease, your child's risk depends entirely on whether your partner is a carrier. Carrier screening for your partner is highly recommended.
In this answer
3 sections
If you have Gaucher disease, you will definitely pass one copy of the mutated gene to each of your children [1]. However, this does not mean your children will automatically be born with the condition. Gaucher disease follows what is known as an autosomal recessive inheritance pattern [2]. This means a child must inherit two mutated genes—one from each parent—to develop the disease [3][4]. If your partner does not have a mutated gene to pass on, your children will be healthy carriers of the condition, but they will not have Gaucher disease themselves [1].
Understanding “Autosomal Recessive” Inheritance
To understand how Gaucher disease is passed down, it helps to look at the GBA1 gene [1]. We all have two copies of the GBA1 gene, one inherited from each parent. This gene provides the instructions for making an enzyme (glucocerebrosidase) that breaks down certain fats in the body [2].
- People with Gaucher disease have two mutated copies of the GBA1 gene [4][3]. Because you have two mutated copies, you will pass one on to every biological child you have [1].
- Carriers have one mutated copy and one normal copy [5]. A carrier typically produces enough of the enzyme to stay healthy and does not have symptoms of Gaucher disease [6]. Because your child is guaranteed to get one mutated gene from you, they will at least be a carrier [1]. Note: While being a carrier means they will not develop Gaucher disease, carrying a mutated GBA1 gene is a known risk factor for developing Parkinson’s disease later in life [7][6].
What Are the Chances for Your Children?
The exact risk to your children depends entirely on your partner’s genetics [3]. Because your genetics do not change over time, your partner only needs to be tested once. Here is how the math breaks down for each pregnancy:
- If your partner is NOT a carrier: There is a 0% chance that your child will have Gaucher disease [1]. Instead, there is a 100% chance your child will be a carrier, inheriting your mutated gene and your partner’s normal gene [1].
- If your partner IS a carrier: There is a 50% chance that your child will inherit Gaucher disease (getting the mutated gene from both of you) [1]. If they do inherit the disease, their specific type and severity (e.g., Type 1 vs. neuropathic Types 2 or 3) will depend heavily on the exact combination of mutations they inherit from both of you [8][9]. There is also a 50% chance they will be a carrier (getting your mutated gene, but your partner’s normal gene) [1].
- If your partner also HAS Gaucher disease: There is a 100% chance your children will inherit the disease, as they will receive a mutated gene from both parents.
Next Steps: Genetic Carrier Screening
Because your partner’s genetics determine the risk for your children, the most important next step is for your partner to undergo genetic carrier screening [3][1].
Carrier screening is a blood or saliva test that looks for mutations in the GBA1 gene [10]. While anyone can be a carrier of Gaucher disease, it is significantly more common in people of Ashkenazi Jewish descent [11][12]. It is important to know that standard carrier screening panels sometimes only test for the most common GBA1 mutations seen in the Ashkenazi Jewish population. If your partner is of a different ethnic background, standard panels might miss a rarer mutation. Full sequencing of the GBA1 gene may be necessary to accurately confirm they are not a carrier [13].
Meeting with a genetic counselor is highly recommended [11][14]. A counselor can help you and your partner arrange the right type of testing and understand your exact risks. If your partner is found to be a carrier, a genetic counselor can also help you explore your options for family planning, which may include:
- In Vitro Fertilization (IVF) with Preimplantation Genetic Testing (PGT): A process to test and select embryos that do not have the disease before a pregnancy begins.
- Prenatal Testing: Testing performed during an active pregnancy to see if the fetus has inherited the disease, such as Chorionic Villus Sampling (CVS) or amniocentesis [11][13].
Common questions in this guide
Do my children automatically get Gaucher disease if I have it?
What are the chances of passing Gaucher disease to my child?
Does my partner need genetic testing for Gaucher disease?
What does it mean to be a carrier of Gaucher disease?
Are there family planning options if both parents carry the GBA1 mutation?
Questions for Your Doctor
5 questions
- •What is my exact GBA1 gene mutation, and what does it tell us about the severity or type of Gaucher disease my children might be at risk for?
- •Based on my partner's ethnic background, do they need full GBA1 gene sequencing, or is a standard carrier screening panel sufficient to confidently rule out a mutation?
- •Can you refer us to a genetic counselor who specializes in lysosomal storage disorders like Gaucher disease?
- •Are genetic testing and genetic counseling typically covered by my health insurance, and does your office assist with prior authorizations for this?
- •If my partner is found to be a carrier, what specific family planning options (like IVF with PGT) or prenatal testing options (like CVS or amniocentesis) would be available to us?
Questions for You
3 questions
- •Have you or your partner ever had genetic testing or general carrier screening in the past, perhaps before a previous pregnancy?
- •Does your partner have any Ashkenazi Jewish ancestry, which would increase the statistical likelihood of them being a carrier for Gaucher disease?
- •How do you and your partner feel about navigating genetic testing and the potential family planning decisions that may follow?
References
References (14)
- 1
Gaucher Disease: Clinical, Biological and Therapeutic Aspects.
Dandana A, Ben Khelifa S, Chahed H, et al.
Pathobiology : journal of immunopathology, molecular and cellular biology 2016; (83(1)):13-23 doi:10.1159/000440865.
PMID: 26588331 - 2
A patient with Gaucher disease and plasma cell dyscrasia: bidirectional impact.
Zimran A, Ruchlemer R, Revel-Vilk S
Hematology. American Society of Hematology. Education Program 2020; (2020(1)):389-394 doi:10.1182/hematology.2020000123.
PMID: 33275748 - 3
Recent advances in the diagnosis and management of Gaucher disease.
Gary SE, Ryan E, Steward AM, Sidransky E
Expert review of endocrinology & metabolism 2018; (13(2)):107-118 doi:10.1080/17446651.2018.1445524.
PMID: 30058864 - 4
Evaluation of Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons from Siblings with Gaucher Disease Discordant for Parkinsonism.
Hertz E, Rytel K, Perez G, et al.
Movement disorders : official journal of the Movement Disorder Society 2025; (40(8)):1719-1724 doi:10.1002/mds.30273.
PMID: 40568761 - 5
Plasma Glucosylsphingosine in GBA1 E365K, N409S, and L483P Heterozygous Mutation Carriers.
Agin-Liebes J, Haimovich A, Griep R, et al.
Movement disorders : official journal of the Movement Disorder Society 2026; doi:10.1002/mds.70205.
PMID: 41552855 - 6
Parkinsonisms and Glucocerebrosidase Deficiency: A Comprehensive Review for Molecular and Cellular Mechanism of Glucocerebrosidase Deficiency.
Gatto EM, Da Prat G, Etcheverry JL, et al.
Brain sciences 2019; (9(2)) doi:10.3390/brainsci9020030.
PMID: 30717266 - 7
GBA1-associated parkinsonism: new insights and therapeutic opportunities.
Ryan E, Seehra G, Sharma P, Sidransky E
Current opinion in neurology 2019; (32(4)):589-596 doi:10.1097/WCO.0000000000000715.
PMID: 31188151 - 8
White vitreous opacities in five patients with Gaucher disease type 3.
Seehra GK, Eghbali A, Sidransky E, FitzGibbon E
American journal of medical genetics. Part A 2020; (182(4)):808-812 doi:10.1002/ajmg.a.61479.
PMID: 31898869 - 9
A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments.
Stirnemann J, Belmatoug N, Camou F, et al.
International journal of molecular sciences 2017; (18(2)) doi:10.3390/ijms18020441.
PMID: 28218669 - 10
Diagnosis and genetic analysis of Gaucher disease in a pediatric case: a case report.
Ma M, Wu N, Feng J, et al.
Frontiers in pediatrics 2025; (13()):1628525 doi:10.3389/fped.2025.1628525.
PMID: 40791806 - 11
Acid β-glucosidase (GBA1) gene mutational spectrum and clinical phenotypes in patients with gaucher disease: seven novel mutations in a multicenter retrospective cohort study from upper Egypt.
Youssef MAM, Elsayed SM, Elsayh KI, et al.
Molecular and cellular pediatrics 2025; (12(1)):14 doi:10.1186/s40348-025-00200-5.
PMID: 41032223 - 12
Gaucher disease: single gene molecular characterization of one-hundred Indian patients reveals novel variants and the most prevalent mutation.
Sheth J, Bhavsar R, Mistri M, et al.
BMC medical genetics 2019; (20(1)):31 doi:10.1186/s12881-019-0759-1.
PMID: 30764785 - 13
Prenatal diagnosis of Gaucher disease using next-generation sequencing.
Yoshida S, Kido J, Matsumoto S, et al.
Pediatrics international : official journal of the Japan Pediatric Society 2016; (58(9)):946-9 doi:10.1111/ped.13069.
PMID: 27682613 - 14
Exploring delayed diagnosis in Gaucher disease: insights from a community survey and potential solutions.
Aragón DPP, Collin-Histed T, Abdelwahab M, et al.
Orphanet journal of rare diseases 2026; doi:10.1186/s13023-026-04209-5.
PMID: 41721348
This page explains the genetic inheritance of Gaucher disease for educational purposes only. Always consult a genetic counselor or healthcare provider to discuss your specific carrier screening and family planning options.
Get notified when new evidence is published on Gaucher Disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.